Please read this notice and click the acknowledgement at the bottom of the page to continue.

Intended Audience:
This webcast is designed for all physician specialists and primary care providers who manage patients with urinary tract disorders, especially those with overactive bladder and related conditions. These clinical disciplines include, but are not limited to: urological specialists, specialists in urologic gynecology, primary care physicians, geriatricians, long-term care directors, women’s health specialists, nurse practitioners, geriatric nurse practitioners, pharmacists and physician assistants

Registration:
Enrollment for this course is complimentary, and clinicians are invited to participate in this CME-certified webcast and/or share this invitation with other colleagues, departmental staff members, and healthcare professionals.

Grantor Support:
Supported by an independent educational grant from Esprit Pharmaceuticals

Accreditation Statement for Jointly-Sponsored Programs:
This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of The University of Massachusetts Medical School and CMEducation Resources, LLC. The University of Massachusetts Medical School is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation Statement:
The University of Massachusetts Medical School designates this educational activity for a maximum of 3 AMA PRA Category 1 Credit(s)^TM. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Policy on Faculty and Provider Disclosure:
It is the policy of the University of Massachusetts Medical School to ensure fair balance, independence, objectivity and scientific rigor in all activities. All faculty participating in CME activities sponsored by the University of Massachusetts Medical School are required to present evidence-based data, identify and reference off-label product use and disclose all relevant financial relationships with those supporting the activity or others whose products or services are discussed. Faculty disclosure will be provided in the activity materials.

Faculty Disclosures:

Scott A. MacDiarmid, MD
Consultant: Pfizer, Ortho-McNeil, Watson, Esprit
Speaker’s Bureau: Novartis, Pfizer, Ortho-McNeil, Watson, Esprit

David R. Staskin, MD
Grant Support: Indevus
Consultant/Speaker: Pfizer, Glaxo, Astellas, Watson, Indevus, Esprit, Novartis, Ortho-McNeil, American Medical Systems

Norman Zinner, MD, MS, FACS
Grant: Indevus, Pfizer, Novartis
Consultant: Indevus, Esprit, Novartis, Pfizer, Ortho-McNeil
Speaker’s Bureau: Esprit, Pfizer

Program Faculty
David R. Staskin, MD
Program Moderator
Associate Professor of Urology
Director, Female Urology and Voiding Dysfunction
Weill Medical College of Cornell University
New York, NY

Norman Zinner, MD, MS, FACS
Medical Director, Western Clinical Research, Inc
Clinical Associate Professor of Urology/Surgery
UCLA School of Medicine
Torrance, CA

Scott MacDiamond, MD
Associate Professor
Director, Wake Forrest University Physicians
Continence Center
Wake Forrest University
Winston-Salem, NC

Educational Objectives:

• Urologists, gynecologists, primary care physicians, geriatricians, and women’s health specialists will learn to screen patients for urinary tract disorders, including overactive bladder, bladder dysfunction, and sub clinical urinary tract infection.
• Urologists, gynecologists, primary care physicians, geriatricians, and women’s health specialists will learn how to confirm the diagnosis of overactive bladder, and learn the appropriate sequence and use of diagnostic modalities used to confirm the diagnosis.
• Urologists, gynecologists, primary care physicians, geriatricians, and women’s health specialists will learn evidence-based approaches to managing urinary tract, with a special focus on differentiating safety, efficacy, and pharmacologic properties of available therapeutic agents.
• Clinicians will learn how to counsel patients with overactive bladder and guide them in measures that improve long-term urinary tract health.
• Clinicians will learn how to implement a systematic approach to diagnostic assessment of patients with urinary frequency, urgency, and related symptoms.
• Clinicians will learn how landmark trials and analyses focusing on overactive bladder should guide pharmacologic therapy.

Copyright (c) 2006 All rights reserved including

I have read the CME information statement

I have not read the CME information statement